Alpha Teknova, Inc. (TKNO)

NASDAQ: TKNO · IEX Real-Time Price · USD
4.94
+0.09 (1.86%)
At close: Dec 2, 2022 4:00 PM
4.70
-0.24 (-4.86%)
After-hours: Dec 2, 2022 5:10 PM EST
1.86%
Market Cap 136.43M
Revenue (ttm) 43.64M
Net Income (ttm) -37.82M
Shares Out 28.09M
EPS (ttm) -0.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 41,349
Open 4.73
Previous Close 4.85
Day's Range 4.65 - 5.06
52-Week Range 3.02 - 22.31
Beta n/a
Analysts Buy
Price Target 10.20 (+106.5%)
Earnings Date Nov 9, 2022

About TKNO

Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmac... [Read more]

Industry Drug Manufacturers-Specialty & Generic
IPO Date Jun 25, 2021
Employees 237
Stock Exchange NASDAQ
Ticker Symbol TKNO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for TKNO stock is "Buy." The 12-month stock price forecast is 10.2, which is an increase of 106.48% from the latest price.

Price Target
$10.2
(106.48% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Teknova Reports Third Quarter 2022 Financial Results

Third quarter 2022 total revenue was $10.7 million, up 14% year-over-year Company updates 2022 revenue outlook to $40-42 million Cash position of $50 million supports path to profitability

3 weeks ago - GlobeNewsWire

Teknova to Participate in Upcoming Investor Conferences

HOLLISTER, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, research, development, and commercializati...

1 month ago - GlobeNewsWire

Teknova to Report Third Quarter 2022 Financial Results on November 9, 2022

HOLLISTER, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug...

1 month ago - GlobeNewsWire

Teknova to Participate in Upcoming Investor Conference

HOLLISTER, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug...

3 months ago - GlobeNewsWire

Teknova Reports Second Quarter 2022 Financial Results

Second quarter 2022 total revenue was $11.7 million, up 41% year-over-year Cash position of $64.7 million supports ongoing investment in growth strategy Company updates 2022 revenue outlook to $38-42 mi...

3 months ago - GlobeNewsWire

Teknova to Report Second Quarter 2022 Financial Results on August 10, 2022

HOLLISTER, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug...

4 months ago - GlobeNewsWire

Teknova Reports First Quarter 2022 Financial Results

First quarter 2022 total revenue was $11.1 million, up 23% year-over-year Excluding Sample Transport revenue, first quarter 2022 total revenue was $11.1 million, up 37% year-over-year Strong cash positi...

6 months ago - GlobeNewsWire

Teknova to Report First Quarter 2022 Financial Results on May 11, 2022

HOLLISTER, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug ...

7 months ago - GlobeNewsWire

Teknova Reports Fourth Quarter and Full Year 2021 Financial Results

Full year 2021 total revenue was $36.9 million, up 18% year-over-year Excluding Sample Transport revenue of $1.5 million, full year 2021 total revenue was $35.4 million, up 31% year-over-year Company pr...

8 months ago - GlobeNewsWire

Teknova to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022

HOLLISTER, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of dru...

9 months ago - GlobeNewsWire

Teknova Announces Preliminary Revenue of $10.0 to $10.1 Million for the Fourth Quarter 2021

Company to participate in two upcoming investor conferences in March 2022 Company to participate in two upcoming investor conferences in March 2022

9 months ago - GlobeNewsWire

Teknova to Join the Nasdaq Biotechnology Index

HOLLISTER, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of biopharmaceutical produ...

11 months ago - GlobeNewsWire

Teknova Reports Third Quarter 2021 Financial Results

$9.4 million in total revenue, up 5% year-over-year Excluding Sample Transport, total revenue was $9.3 million, up 26% year-over-year Strong cash position of $98.0 million supports investment in long-te...

1 year ago - GlobeNewsWire

Teknova to Report Third Quarter 2021 Financial Results on November 10, 2021

HOLLISTER, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of biopharmaceutical produ...

1 year ago - GlobeNewsWire

Teknova Reports Second Quarter 2021 Financial Results

—$8.3 million in total revenue, up 38% year-over-year—

1 year ago - GlobeNewsWire

Teknova Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additi...

HOLLISTER, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of biopharmaceutical produ...

1 year ago - GlobeNewsWire

7 Companies Go Public Today. What Investors Need to Know.

Acurx Pharmaceuticals, Alpha Teknova, Elevation Oncology, GH Research, Graphite Bio, and MissFresh are listed on the Nasdaq. Mister Car Wash is trading the New York Stock Exchange.

Other symbols: ELEVGHRSGRPHMCWACXPMF
1 year ago - Barrons

Teknova Announces Pricing of its Upsized Initial Public Offering

HOLLISTER, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of biopharmaceutical produ...

1 year ago - GlobeNewsWire